Montai Therapeutics
Cambridge
About Montai Therapeutics
Montai is harnessing nature's power through digital technology to treat and prevent chronic disease, hence improving health outcomes for as many people as possible. To address this crucial global concern, the business is pioneering cutting-edge technology to develop AnthromoleculeTM medications, which are derived from a privileged class of compounds with a history of safe human use. Our human-centered foundation can enable the rapid and repeatable development of safe, efficacious, and accessible medicines for as many diseases and people as possible by creating the world's first Anthromolecule Bioactivity Atlas, which comprehensively maps potent connections to all known biological pathways underlying disease.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $50.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Dec 2022)
- Website: montai.com
Industries & Categories
Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/montai-therapeutics-56836 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.